Hypercholesterolemia

Drugs of Today

Volumn 33, Issue 5, 1997, Pages 307-314

  Rackley, Charles E ^a  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CORONARY ARTERY DISEASE; DIETARY INTAKE; DISEASE ASSOCIATION; HUMAN; HYPERCHOLESTEROLEMIA; LIFESTYLE; LIPOPROTEIN BLOOD LEVEL; MORTALITY; PREVALENCE; REVIEW; RISK ASSESSMENT; RISK FACTOR;

EID: 0030835989     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: None     Document Type: Review

References (14)

1. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Summary of the second report of the National Cholesterol Education Program (NECP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (adult treatment panel No. 2). JAMA 1993, 269: 3015-23.
2. Kannel, W.B. Lipids, diabetes, and coronary heart disease: Insights from the Framingham study. Am Heart J 1985, 110 (5): 1100-7.
3. Multiple Risk Factor Intervention Trial Research Group. Multiple risk factor intervention trial: Risk factor changes and mortality results. JAMA 1982, 248 (12): 1465-77.
4. Romm, P.A., Green, C.E., Regan, K., Rackley, C.E. Relationship of serum lipoprotein cholesterol levels to presence and severity of angiography coronary artery disease. Am J Cardiol 1991, 67: 479-83.
5. Jones, P.H., Patsch, J., Gotto, A.M. Jr. The biochemistry of blood lipid regulation and the assessment of lipid abnormalities. In: Hurst's The Heart, 8th Ed. Schlant, R.S., Alexander, R.W. (Eds.). McGraw-Hill: New York 1994, 973-87.
6. Steinberg, D., Parthasarathy, S., Carew, T.E., Khoo, J.C., Witztum, J.L. Beyond cholesterol. Modifications of low density lipoprotein that increases atherogenicity. New Engl J Med 1989, 320: 915-24.
7. Steinberg, D., Lewis, A. Conner Memorial Lecture. Oxidative modification of LDL and atherogenesis. Circulation 1997, 95: 1062-71.
8. Berliner, J.A., Navab, M., Fogelman, A.M. et al. Atherosclerosis: Basic mechanisms, oxidation, inflammation and genetics. Circulation 1995, 91: 2488-96.
9. Bui, M.N., Sack, M.N., Moutsatsos, G. et al. Autoantibody titers to oxidized low density lipoprotein in patients with coronary atherosclerosis. Am Heart J 1996, 131: 663-7.
10. Libby, T. Molecular bases of the acute coronary syndrome. Circulation 1995, 91: 2844-50.
11. Falk, E., Shah, P.K., Fuster, V. Coronary plaque disruption. Circulation 1995, 92: 657-71.
12. Rackley, C.E., Schlant, R.S. Prevention of coronary artery disease. In: Hurst's The Heart, 8th Ed. Schlant, R.S., Alexander, R.W. (Eds.). McGraw-Hill; New York 1994, 1205-22.
13. Rackley, C.E. Monotherapy with HMG-CoA reductase inhibitors and secondary prevention in coronary artery disease. Clin Cardiol 1996, 19: 683-9.
14. Rackley, C.E. Contemporary treatment of lipid abnormalities. Contemp Treat Cardiovasc Dis 1996, 1: 49-58.